var data={"title":"Desflurane: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Desflurane: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5988?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=desflurane-patient-drug-information\" class=\"drug drug_patient\">see &quot;Desflurane: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157562\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Suprane</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157563\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Suprane</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157589\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        General Anesthetic, Inhalation</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157567\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosage must be individualized based on patient response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Anesthesia, induction:</b> Initial: Inhaled concentration of 3%, increased by 0.5% to 1% increments every 2 to 3 breaths (end tidal concentrations 4% to 11%). Inspired concentrations &gt;12% have been safely administered during induction and may require a reduction of nitrous oxide or air.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anesthesia, maintenance:</b> Inhaled concentrations of 2.5% to 8.5% with or without concomitant nitrous oxide.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The minimum alveolar concentration (MAC), the concentration at which 50% of patients do not respond to surgical incision, varies by age. In adults, the concentration at which amnesia and loss of awareness occur (MAC - awake) is 2.4%. Surgical levels of anesthesia are maintained between 2.5% to 8.5%.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th colspan=\"3\" align=\"center\">\n            <p style=\"text-indent:0em;\">Patient Age and Minimum Alveolar Concentration (MAC)</p></th></tr></thead>\n      <tfoot valign=\"top\">\n        <tr>\n          <td colspan=\"3\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <b>Note:</b> Concurrent use with benzodiazepines, nitrous oxide, or opioids decreases desflurane dose. Because of the higher vapor pressure of desflurane, its vaporizer is heated in order to deliver a constant concentration.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Age</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>MAC with 100% Oxygen</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>MAC with 60% N<sub>2</sub>O/40% Oxygen</b></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25 y</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.3%</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4%</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">45 y</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6%</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.8%</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">70 y</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.2%</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.7%</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157578\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosage must be individualized based on patient response. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anesthesia, maintenance: </b>Children: Inhaled concentrations of 5.2% to 10% with or without nitrous oxide.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">The minimum alveolar concentration (MAC), the concentration at which 50% of patients do not respond to surgical incision, varies by age. Surgical levels of anesthesia are maintained between 5.2% and 10% in children. </p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th colspan=\"3\" align=\"center\">\n            <p style=\"text-indent:0em;\">Patient Age and Minimum Alveolar Concentration (MAC)</p></th></tr></thead>\n      <tfoot valign=\"top\">\n        <tr>\n          <td colspan=\"3\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <b>Note:</b> Concurrent use with benzodiazepines, nitrous oxide, or opioids decreases desflurane dose. Because of the higher vapor pressure of desflurane, its vaporizer is heated in order to deliver a constant concentration.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Age</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>MAC with 100% Oxygen</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>MAC with 60% N<sub>2</sub>O/40% Oxygen</b></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9 mo</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10%</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.5%</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 y</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8.9%</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6.4%</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157568\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">The mean alveolar concentrations decrease with increasing age; adjust dose accordingly. Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15796016\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15796017\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157549\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Suprane: 100% (240 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157539\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157551\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Inhalation: Via desflurane-specific calibrated heated vaporizer</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157550\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>US labeling: </i></b> <b>Anesthesia:</b> For induction of anesthesia in adults and maintenance of anesthesia in adults and pediatric patients for inpatient and outpatient surgery. <b>Note:</b> Use of desflurane for induction of general anesthesia in adult patients may not be suitable due to its irritant properties and unpleasant odor which may cause coughing, breath-holding, laryngospasm, oxygen desaturation, increased secretions, hypertension, and tachycardia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desflurane is contraindicated for induction of anesthesia in nonintubated pediatric patients because of a high incidence of moderate to severe upper airway adverse events. After induction of anesthesia with agents other than desflurane, and tracheal intubation, desflurane is indicated for maintenance of anesthesia in infants and children.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Canadian labeling: </i></b> <b>Anesthesia:</b> For maintenance of general anesthesia following induction with alternative agents (adults and pediatric patients) and subsequent endotracheal intubation (pediatric patients).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Limitations of use: Use for induction of anesthesia is not recommended in adults and contraindicated in pediatric patients due to a high incidence of moderate to severe upper airway adverse events.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157595\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Desflurane may be confused with Desferal</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157544\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (27%), vomiting (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (3% to 34%), breath-holding (&gt;1% to 30%), apnea (3% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Oxygen saturation decreased (3% to 10%), bradycardia, hypertension (including malignant hypertension), nodal arrhythmia, shivering, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Sialorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Laryngospasm (3% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Increased bronchial secretions (3% to 10%), pharyngitis (&gt;1% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, acute pancreatitis, agitation, asthma, atrial fibrillation, bigeminy, blood coagulation disorder, bronchospasm, cardiac arrhythmia, cholestasis, dizziness, dyspnea, ECG abnormality, erythema, fever, hemoptysis, hemorrhage, hepatic failure, hepatic necrosis, hepatitis (including cytolytic hepatitis), hepatotoxicity (Chung 2003; Cote 2007), hyperammonemia, hyperkalemia, hypokalemia, hypokinesia (ventricular), hypotension, hypoxia, increased serum creatinine, increased serum transaminases, ischemic heart disease, jaundice, leukocytosis, malaise, malignant hyperthermia, metabolic acidosis, myocardial infarction, myalgia, pruritus, respiratory distress, respiratory failure, rhabdomyolysis, scleral icterus, seizure, shock, torsades de pointes, urticaria, vasodilatation, ventricular dysfunction, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157554\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to desflurane, other halogenated agents, or any component of the formulation; known or suspected genetic susceptibility to malignant hyperthermia; patients in whom general anesthesia is contraindicated; induction of anesthesia in pediatric patients; history of moderate to severe hepatic impairment following anesthesia with desflurane or other halogenated agents and not otherwise explained.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): History of hepatitis due to a halogenated inhalational anesthetic or in whom hepatic dysfunction, jaundice or unexplained fever, leukocytosis, or eosinophilia has occurred after previous halogenated anesthetic administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157542\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Decreased blood flow: May cause decrease in hepatic and/or renal blood flow.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatitis: May cause sensitivity hepatitis in patients who have been sensitized by previous exposure to halogenated anesthetics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: Use of inhaled anesthetics has been associated with rare cases of perioperative hyperkalemia (including fatalities) in pediatric patients; concomitant use of succinylcholine was associated with many of the reported cases, but not all. Risk of hyperkalemia is increased in patients with underlying neuromuscular disease (eg, Duchenne muscular dystrophy). Other abnormalities may include elevation in CK and myoglobinuria. Monitor closely for arrhythmias. Aggressively identify and treat hyperkalemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased intracranial pressure: May dilate the cerebral vasculature and may, in certain conditions, increase intracranial pressure. In patients with intracranial space-occupying lesions, administer at &le;0.8 MAC in conjunction with a barbiturate induction and hyperventilation in the period before cranial decompression; maintain cerebral perfusion pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignant hyperthermia: May trigger malignant hyperthermia (MH); some reported cases have been fatal. Use is contraindicated in patients susceptible to MH.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT prolongation: Cases of QT prolongation in association with torsade de pointes (some fatal) have been reported with inhaled anesthetic agents; use caution when administering to patients at risk of QT prolongation (eg, concurrent use of drugs that can prolong the QT interval, such as class Ia and III antiarrhythmic drugs, elderly patients, congenital QT prolongation) (Han 2010; Kang 2006; Nakao 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory depression: Causes dose-dependent respiratory depression and blunted ventilatory response to hypoxia and hypercapnia. Hypoxic pulmonary vasoconstriction is blunted which may lead to increased pulmonary shunt. May produce elevated carbon monoxide levels and carboxyhemoglobin in the presence of a desiccated dry carbon dioxide absorbent within the circle breathing system of an anesthetic machine; barium hydroxide and soda lime desiccation have been reported when fresh gasses are passed over a carbon dioxide canister at high flow rates over many hours or days. Maintain fresh absorbent as per manufacturer guidelines regardless of state of colorimetric indicator.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Do not use as a single agent to induce anesthesia in patients with CAD or in whom an increase in heart rate or blood pressure should be avoided. Abrupt increases in inspired concentrations &gt;1 MAC can produce a transient increase in blood pressure and heart rate due to increased plasma catecholamine levels. Acute, rapid increases in desflurane concentration can produce increased sympathetic cardiovascular stimulation which lasts for 2 to 4 minutes; can be blunted by concurrent use of nitrous oxide, opioids, beta-blockers, and alpha-2 agonists (Weiskopf 1994). Hypotensive effect due to peripheral vasodilation is dose dependent and increases as anesthesia is deepened. In a scientific statement from the American Heart Association, desflurane has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic disease: Due to the risk of hepatitis with halogenated anesthetics, use in patients with cirrhosis, viral hepatitis, or other preexisting hepatic disease should be approached with caution; disruption of hepatic function, icterus, and fatal liver necrosis have been reported and may indicate hypersensitivity. Consider the use of an anesthetic other than a halogenated anesthetic.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Postoperative agitation may occur in children while emerging from anesthesia. Contraindicated for induction of general anesthesia in pediatric patients due to the higher incidence of moderate to severe upper airway adverse events (eg, laryngospasm, coughing, breath-holding, increased secretions). Do not use to maintain anesthesia in nonintubated pediatric patients. Use with caution when used to maintain anesthesia in children &le;6 years when a laryngeal mask airway (LMA) is in place due to the increased potential for adverse respiratory effects especially with removal of the LMA under deep anesthesia. Use with caution in children with asthma or recent upper respiratory infection; increased risk for airway narrowing and increased airway resistance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric neurotoxicity: In pediatric and neonatal patients &lt;3 years and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on child or fetal brain development and may contribute to various cognitive and behavioral problems. Epidemiological studies in humans have reported various cognitive and behavioral problems including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk vs benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Occupational caution: Although there are no documented adverse effects of chronic occupational exposure to halogenated anesthetic vapors, like desflurane, some epidemiological studies suggest a link between these anesthetics and increased health problems (particularly spontaneous abortion). There is no specific work exposure limit established for desflurane. However, the National Institute for Occupational Safety and Health (NIOSH) has recommended that workers should not be exposed to ceiling concentrations greater than 2 ppm of any halogenated anesthetic agent over a period &le;1 hour. The predicted effects of acute overexposure by inhalation of desflurane include headache, dizziness, or (in extreme cases) unconsciousness. Precautions (eg, adequate ventilation, scavenging-systems, minimizing leaks/spills) can help to lessen any potential risk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Monitoring: Transient elevations in white blood cell count and glucose may occur.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299135\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157545\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8891&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bambuterol: May enhance the arrhythmogenic effect of Inhalational Anesthetics. Management: Some labels recommend specifically avoiding halothane; others recommend separating administration by at least 6 hours; other bambuterol labels do not mention this possible interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOPamine: Inhalational Anesthetics may enhance the arrhythmogenic effect of DOPamine.  Management: Avoid use of dopamine in patients receiving halogenated hydrocarbon anesthetics.  If concomitant treatment cannot be avoided, monitor for arrhythmia.  Dopamine induced ventricular arrhythmia may be reversible with propranolol based on animal data.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ephedra: May enhance the arrhythmogenic effect of Inhalational Anesthetics.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPHEDrine (Nasal): May enhance the arrhythmogenic effect of Inhalational Anesthetics.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPHEDrine (Systemic): May enhance the arrhythmogenic effect of Inhalational Anesthetics.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPINEPHrine (Nasal): Inhalational Anesthetics may enhance the arrhythmogenic effect of EPINEPHrine (Nasal). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPINEPHrine (Oral Inhalation): Inhalational Anesthetics may enhance the arrhythmogenic effect of EPINEPHrine (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPINEPHrine (Systemic): Inhalational Anesthetics may enhance the arrhythmogenic effect of EPINEPHrine (Systemic).  Management: Administer epinephrine with added caution in patients receiving, or who have recently received, inhalational anesthetics. Use lower than normal doses of epinephrine and monitor for the development of cardiac arrhythmias.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fenoterol: Inhalational Anesthetics may enhance the arrhythmogenic effect of Fenoterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Formoterol: Inhalational Anesthetics may enhance the arrhythmogenic effect of Formoterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoproterenol: Inhalational Anesthetics may enhance the arrhythmogenic effect of Isoproterenol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaraminol: Inhalational Anesthetics may enhance the arrhythmogenic effect of Metaraminol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the hypertensive effect of Inhalational Anesthetics.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): Inhalational Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Norepinephrine: Inhalational Anesthetics may enhance the arrhythmogenic effect of Norepinephrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: May enhance the adverse/toxic effect of Inhalational Anesthetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4323389\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Based on animal data, repeated or prolonged use of general anesthetic and sedation medications that block N-methyl-D- aspartate (NMDA) receptors and/or potentiate gamma-aminobutyric acid (GABA) activity, may affect brain development. Human fetuses may be most vulnerable during the third trimester. Until additional information is available, the benefits and risks of maternal treatment with desflurane during pregnancy should be evaluated, especially for procedures lasting more than 3 hours. The ACOG recommends that pregnant women should not be denied medically indicated surgery or procedures, regardless of trimester. If the procedure is elective, it should be delayed until after delivery (ACOG 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4323391\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if desflurane is present in breast milk. The manufacturer recommends that caution be exercised when administering desflurane to nursing women. Due to rapid washout, desflurane levels in milk most likely have no clinical importance 24 hours after anesthesia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157547\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;\">Blood pressure, heart rate and rhythm, temperature, oxygen saturation, end-tidal CO<sub>2</sub> and end-tidal desflurane concentrations should be monitored prior to and throughout anesthesia; adverse respiratory symptoms in pediatric patients (&le;6 years); signs and symptoms of airway narrowing in children with asthma or recent upper respiratory infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002849\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Although not completely defined, it is thought that desflurane enhances inhibitory postsynaptic channel activity and inhibits excitatory synaptic activity resulting in general anesthesia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157553\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: 1 to 2 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Emergence time: Depends on blood concentration when desflurane is discontinued</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The rate of change of anesthetic concentration in the lung is more rapid with desflurane because of its low blood/gas solubility (0.42), which is similar to nitrous oxide.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic (0.02%) to trifluoroacetate (negligible) and inorganic fluoride</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Exhaled gases</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157556\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Sulorane (IL);</li>\n      <li>Suprane (AE, AR, AT, AU, BE, BH, CH, CN, CY, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HN, HU, ID, IE, IS, IT, JP, KR, KW, LU, MT, MY, NL, NO, NZ, PE, PL, QA, RO, SA, SE, SG, SK, TH, TR, TW, VE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 474: nonobstetric surgery during pregnancy. <i>Obstet Gynecol</i>. 2011;117(2 pt 1):420-421.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desflurane-drug-information/abstract-text/21252774/pubmed\" target=\"_blank\" id=\"21252774\">21252774</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Campagna JA, Miller KW, and Forman SA, &ldquo;Mechanisms of Actions of Inhaled Anesthetics,&rdquo;<i>N Engl J Med</i>, 2003, 348(21):2110-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desflurane-drug-information/abstract-text/12761368/pubmed\" target=\"_blank\" id=\"12761368\">12761368</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desflurane-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Hert SG, Turani F, Mathur S, et al, &ldquo;Cardioprotection With Volatile Anesthetics: Mechanisms and Clinical Implications,&rdquo; <i>Anesth Analg</i>, 2005, 100(6):1584-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desflurane-drug-information/abstract-text/15920178/pubmed\" target=\"_blank\" id=\"15920178\">15920178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ebert TJ and Muzi M, &ldquo;Sympathetic Hyperactivity During Desflurane Anesthesia in Healthy Volunteers. A Comparison With Isoflurane,&rdquo; <i>Anesthesiology</i>, 1993, 79(3):444-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desflurane-drug-information/abstract-text/8363068/pubmed\" target=\"_blank\" id=\"8363068\">8363068</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Food and Drug Administration. FDA Drug Safety Communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women. <a href=\"https://www.fda.gov/Drugs/DrugSafety/ucm53235\" target=\"_blank\">https://www.fda.gov/Drugs/DrugSafety/ucm53235</a>. Updated April 27, 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desflurane-drug-information/abstract-text/8363068/pubmed\" target=\"_blank\" id=\"8363068\">8363068</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guarracino F, Landoni G, Tritapepe L, et al, &ldquo;Myocardial Damage Prevented by Volatile Anesthetics: A Multicenter Randomized Controlled Study,&rdquo; <i>J Cardiothorac Vasc Anesth</i>, 2006, 20(4):477-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desflurane-drug-information/abstract-text/16884976/pubmed\" target=\"_blank\" id=\"16884976\">16884976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Han DW, Park K, Jang SB, Kern SE. Modeling the effect of sevoflurane on corrected QT prolongation: a pharmacodynamic analysis. <i>Anesthesiology</i>. 2010;113(4):806-811.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desflurane-drug-information/abstract-text/20808206/pubmed\" target=\"_blank\" id=\"20808206\">20808206</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kang J, Reynolds WP, Chen XL, et al. Mechanisms underlying the QT interval-prolonging effects of sevoflurane and its interactions with other QT-prolonging drugs. <i>Anesthesiology</i>. 2006;104(5):1015-1022.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desflurane-drug-information/abstract-text/16645454/pubmed\" target=\"_blank\" id=\"16645454\">16645454</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meco M, Cirri S, Gallazzi C, et al, &ldquo;Desflurane Preconditioning in Coronary Artery Bypass Graft Surgery: A Double-Blinded, Randomised and Placebo-Controlled Study,&rdquo; <i>Eur J Cardiothorac Surg</i>, 2007, 32(2):319-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desflurane-drug-information/abstract-text/17574858/pubmed\" target=\"_blank\" id=\"17574858\">17574858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nakao S, Hatano K, Sumi C, et al. Sevoflurane causes greater QTc interval prolongation in elderly patients than in younger patients. <i>Anesth Analg</i>. 2010;110(3):775-779.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desflurane-drug-information/abstract-text/20185656/pubmed\" target=\"_blank\" id=\"20185656\">20185656</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desflurane-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sakai EM, Connolly LA, and Klauck J, &ldquo;Inhalation Anesthesiology and Volatile Liquid Anesthetics: Focus on Isoflurane, Desflurane, and Sevoflurane,&rdquo; <i>Pharmacotherapy</i>, 2005, 25(12):1773-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desflurane-drug-information/abstract-text/16305297/pubmed\" target=\"_blank\" id=\"16305297\">16305297</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suprane (desflurane) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suprane (desflurane) [product monograph]. Mississauga, Ontario, Canada: Baxter Corporation; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tritapepe L, Landoni G, Guarracino F, et al, &ldquo;Cardiac Protection by Volatile Anaesthetics: A Multicentre Randomized Controlled Study in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass,&rdquo; <i>Eur J Anaesthesiol</i>, 2007, 24(4):323-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desflurane-drug-information/abstract-text/17156509/pubmed\" target=\"_blank\" id=\"17156509\">17156509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang L, Traystman RJ, and Murphy SJ, &ldquo;Inhalational Anesthetics as Preconditioning Agents in Ischemic Brain,&rdquo; <i>Curr Opin Pharmacol</i>, 2008, 8(1):104-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desflurane-drug-information/abstract-text/17962069/pubmed\" target=\"_blank\" id=\"17962069\">17962069</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weiskopf RB, Eger EI 2nd, Noorani M, et al, &ldquo;Fentanyl, Esmolol, and Clonidine Blunt the Transient Cardiovascular Stimulation Induced by Desflurane in Humans,&rdquo; <i>Anesthesiology</i>, 1994, 81(6):1350-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desflurane-drug-information/abstract-text/7992902/pubmed\" target=\"_blank\" id=\"7992902\">7992902</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weiskopf RB, Moore MA, Eger EI 2nd, et al, &ldquo;Rapid Increase in Desflurane Concentration Is Associated With Greater Transient Cardiovascular Stimulation Than With Rapid Increase in Isoflurane Concentration in Humans,&rdquo; <i>Anesthesiology</i>, 1994, 80(5):1035-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desflurane-drug-information/abstract-text/8017643/pubmed\" target=\"_blank\" id=\"8017643\">8017643</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yasuda N, Lockhart SH, Eger EI 2nd, et al, &ldquo;Kinetics of Desflurane, Isoflurane, and Halothane in Humans,&rdquo; <i>Anesthesiology</i>, 1991, 74(3):489-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desflurane-drug-information/abstract-text/2001028/pubmed\" target=\"_blank\" id=\"2001028\">2001028</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8891 Version 143.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F157562\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F157563\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F157589\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F157567\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F157578\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F157568\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15796016\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15796017\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F157549\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F157539\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F157551\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F157550\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F157595\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F157544\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F157554\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F157542\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299135\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F157545\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F4323389\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F4323391\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F157547\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8002849\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F157553\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F157556\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8891|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=desflurane-patient-drug-information\" class=\"drug drug_patient\">Desflurane: Patient drug information</a></li></ul></div></div>","javascript":null}